BioNotebook Deals and Data: Zosano/Novo, MacroGenics/Servier, Regulus/Sanofi, Seattle Genetics/Takeda, Sarepta
This article was originally published in Scrip
Executive Summary
Zosano and Novo agree to make GLP-1 patches; Servier exercises option for MacroGenics antibody; Sanofi expands alliance with Regulus; Seattle Genetics earns milestone from Takeda; and Sarepta reports pulmonary data for eteplirsen.
You may also be interested in...
MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.